FDA issues warning letter to Happiest Baby over unapproved SNOO sleep sacks, Hospital Bundle. The agency cited the manufacturer for distributing new sleep sack sizes and a clinical bassinet bundle without required clearance, alongside quality system and reporting violations. Key takeaways: * The FDA issued a warning letter to Happiest Baby, Inc for marketing X-Small and X-Large SNOO sleep sacks and a SNOO Hospital Bundle without proper agency authorization. * The unauthorized sleep sack sizes pose increased risks to infants, including potential respiratory compromise and suffocation, due to dimensional changes not evaluated in the device's original clearance, according to the FDA. * Marketing the SNOO for hospital use fundamentally alters its intended environment, introducing new risks related to infection control protocols and mobility cart stability. * The manufacturer was also cited for quality system violations, including inadequate complaint handling regarding reports of mold and soiling on refurbished devices. The US Food and Drug Administration (FDA) issued a warning letter on June 15, 2026, to Happiest Baby, Inc, the manufacturer of the SNOO Smart Sleeper, citing multiple violations that include the distribution of unapproved sleep sack sizes and a hospital bassinet bundle. The SNOO Smart Sleeper was originally authorized for home use to facilitate a supine sleep position for infants up to 6 months old, utilizing three specific sleep sack sizes (small, medium, and large). However, an FDA inspection revealed the company introduced X-Small (4-8 lbs) and X-Large (23-25 lbs) sleep sacks without submitting the required premarket notification (510(k)). According to the FDA, the dimensional changes in the unapproved sleep sacks significantly alter the device's risk profile. The X-Small sleep sack poses a risk of compressing vital organs and limiting diaphragmatic movement, while the X-Large size increases the risk of the fabric riding up and covering an infant's mouth or neck, potentially leading to respiratory compromise or suffocation. The warning letter also addressed the SNOO Hospital Bundle, which is marketed for clinical settings. The FDA stated that transitioning the device from home use to hospital use, including in neonatal intensive care units, constitutes a major change in intended use. The hospital environment introduces unique challenges, such as the need for hospital-grade cleaners that could degrade device components, and the inclusion of a wheeled mobility cart that presents new risks of tipping or rolling during transport. Additionally, the FDA cited Happiest Baby for quality system regulation violations. Investigators found the company inadequately handled customer complaints by grouping multiple reports - such as instances of mold on mattresses or sleep sacks being too large - without evaluating each case individually. The firm also failed to submit required reports to the FDA within 10 working days after initiating a correction to replace stained and soiled refurbished SNOO devices. The agency noted that improperly cleaned SNOO devices can pose health risks for the vulnerable infant population, as exposure to contaminated surfaces and bodily fluid stains may cause local and systemic infections. The FDA has requested a written response from Happiest Baby outlining the specific steps the firm has taken to address the noted violations and prevent their recurrence.

Small Sleep sacks, big Compliance lessons: what FDA's Happiest Baby Warning Letter means for device manufacturers. On June 15, 2026, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to Happiest Baby, Inc., the manufacturer of the SNOO Smart Sleeper bassinet system, following a July 2025 inspection of the company's Los Angeles facility. The Warning Letter highlights several key points related to complaint handling, premarket notification requirements, field correction reporting, design changes, and unauthorized changes to the device's intended use environment, with important lessons for device manufacturers of all sizes. 1. Bundling of Complaints: Why Grouping Multiple Complaints Undermines MDR Compliance FDA cited Happiest Baby for failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints and for failure to maintain adequate records of complaint investigations. The core deficiency was the firm's practice of "bundling" - grouping several distinct customer complaints related to the same overarching topic, e.g., the sleep sack being too large, together in the complaint system as a single complaint record. FDA reviewed 17 complaints during the inspection and found that 9 of 17 reflected this bundling practice, with the firm performing complaint handling activities (including complaint investigations and Medical Device Report (MDR) determinations) under a single complaint entry for multiple distinct events. Bundling complaints can be problematic for several reasons. It can limit the extent of the investigation for each individual case, potentially masking safety signals that would be apparent if complaints were evaluated independently, thereby risking a single non-reportability determination being applied to events that, if individually assessed, might meet the threshold for mandatory MDR reporting. Bundling can also obscure the frequency and severity of particular failure modes, which are critical inputs to both MDR determinations and Corrective and Preventive Action (CAPA) evaluations, and undermine trending analyses that quality systems rely on to identify emerging risks. 2. Product Modifications After De Novo Authorization: Evaluating When a New Premarket Submission Is Required and Implementing Design Controls Under 21 CFR 807.81(a)(3), a manufacturer must submit a new premarket notification (510(k)) before commercially distributing a device that has been changed or modified in a manner that could significantly affect its safety or effectiveness, or that constitutes a major change or modification in its intended use. FDA's guidance document, Deciding When to Submit a 510(k) for a Change to an Existing Device, provides a decision framework for this assessment. The SNOO Smart Sleeper was authorized under De Novo classification request DEN210039 with an indication specifying three sizes of sleep sacks: Small (5-12 lbs), Medium (12-18 lbs), and Large (18-25 lbs). FDA found that Happiest Baby had introduced two additional sizes - an X-Small Sleep Sack (4-8 lbs) and an X-Large Sleep Sack (23-25 lbs) - without submitting a premarket notification. FDA concluded that the X-Small Sleep Sack constituted both a change that could significantly affect safety or effectiveness and a major change in intended use. Notably, the firm first distributed the X-Small Sleep Sack in a beta program in direct response to customer complaints that the Small Sleep Sack was too large - the very same complaints it had bundled and found non-reportable. The X-Large Sleep Sack also constituted a change that could significantly affect safety or effectiveness, because babies in the weight range for the X-Large Sleep Sack also are within the bounds of the weight for the Large Sleep Sack, so the larger size may make it easier for an infant to break free from the sleep sack and assume an unsafe position in the bassinet. FDA also cited Happiest Baby for failure to adequately establish and maintain procedures for the identification, documentation, validation or, where appropriate, verification, review, and approval of design changes before implementation. FDA viewed the sleep sack size changes and related product iterations as design changes that should have moved through formal design-control procedures - not merely customer service resolution, beta testing, or commercial rollout "based on equivalency to prior testing" and reliance on prior validation protocols, reports, and justifications. The lesson for manufacturers is that complaint-driven modifications can trigger multiple, overlapping regulatory workstreams: complaint investigation, MDR assessment, CAPA evaluation, design-change control, and premarket submission analysis. A change intended to resolve a safety-related complaint should be documented through the design history file and supported by verification or validation before implementation or distribution. 3. Reporting Obligations Under 21 CFR Part 806: Corrections and Removals Under 21 CFR Part 806, manufacturers and importers must report to FDA any correction or removal of a medical device initiated to reduce a risk to health posed by the device, or to remedy a violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) caused by the device that may present a risk to health. Such reports must be submitted within 10 working days of initiating the correction or removal. FDA found that Happiest Baby had been sending replacement SNOO Smart Sleeper devices to customers who returned stained, soiled, or otherwise unsanitary units. FDA determined that this action constituted a correction or removal within the meaning of the regulation - it was initiated to reduce a risk to health posed by the device or to remedy a violation of the FD&C Act - and that the firm failed to file the required report. This citation is a reminder that Part 806 reporting obligations can be triggered by activities that a manufacturer might not reflexively classify as a "recall." Product replacement programs, refurbishment exchanges, and field service actions that address customer complaints may satisfy the regulatory definition of a correction or removal if they are undertaken to reduce a risk to health. Manufacturers should ensure that product replacements are evaluated under Part 806 to determine whether the replacements meet the definition of a correction or removal. 4. Change of Intended Use Location: From Home to Hospital When FDA granted the De Novo request for the SNOO Smart Sleeper under DEN210039, it authorized the device "for home use by caregivers." FDA found that Happiest Baby was marketing and distributing a "SNOO Hospital Bundle" to hospitals - a package that included the SNOO Smart Sleeper bassinet, a mobility cart, a reusable sealed mattress, mesh covers, sleep sacks, fitted sheets, and disposable cover sets. The Hospital Bundle was marketed with claims that it keeps sleeping babies safely on their backs - an intended use very similar to the authorized home-use indication. FDA concluded that marketing the SNOO Smart Sleeper for use in hospital settings constituted a major change or modification in intended use and a change or modification that could significantly affect safety or effectiveness - for example, the mobility cart introduced new risks not evaluated in the original authorization, including reliance on wheel locks to prevent unintended movement and the potential for the cart to roll or tip over while an infant is in the bassinet. Happiest Baby argued that the SNOO, when used in the hospital, was not a medical device because it was marketed exclusively as a soothing tool. FDA rejected this characterization, finding that the Hospital Bundle is a device, that its intended use is not a general wellness use, and that CDRH's general wellness policy did not apply because the bundle did not present a low risk to safety. This finding illustrates that the environment of use is a critical element of a device's authorized intended use. Moving a device from home to clinical settings can fundamentally change the risk profile and require premarket evaluation. This also demonstrates that recharacterizing an authorized medical device as a "wellness" or "non-medical" product for a new market segment is unlikely to succeed when the product's claims and function remain substantially the same as the authorized intended use. *************** This Warning Letter identifies systemic vulnerabilities that can emerge in any medical device company. FDA Law Blog is available to help ensure that your processes and systems are designed to mitigate the risk of a similar outcome. Search FDA Law Blog. Subscribe. Never miss a post from FDA Law Blog

A mom is shocked after a Happiest Baby SNOO bassinet purchase came with hidden subscription fees to access its features.